Page last updated: 2024-10-27

fenoldopam and Heart Diseases

fenoldopam has been researched along with Heart Diseases in 1 studies

Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stone, GW1
McCullough, PA1
Tumlin, JA1
Lepor, NE1
Madyoon, H1
Murray, P1
Wang, A1
Chu, AA1
Schaer, GL1
Stevens, M1
Wilensky, RL1
O'Neill, WW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury[NCT01098032]Phase 3294 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Contrast-induced Acute Kidney Injury

The primary outcome measure will be the rate of development of CI-AKI in the 2 study arms (number of participants). CI-AKI is defined as an increase in the serum creatinine concentration >=0.3 mg/dL from the baseline value at 48 hours after administration of the contrast media or the need for dialysis. (NCT01098032)
Timeframe: at 48 hours following contrast exposure

Interventionparticipants (Number)
Systemic Alone Therapy Group146
RenalGuard System Group146

Trials

1 trial available for fenoldopam and Heart Diseases

ArticleYear
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
    JAMA, 2003, Nov-05, Volume: 290, Issue:17

    Topics: Adult; Aged; Angiography; Angioplasty, Balloon, Coronary; Contrast Media; Creatinine; Dopamine Agoni

2003